Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 18,729 | 14,219 | 19,532 | 15,286 | 17,130 |
| TOTAL | $22,037 | $16,244 | $21,082 | $17,189 | $21,455 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $22,037 | $16,244 | $21,082 | $17,189 | $21,455 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,327 | 5,276 | 2,591 | 2,112 | 974 |
| Accrued Expenses | 3,032 | 7,515 | 1,045 | 1,622 | 1,831 |
| TOTAL | $6,359 | $12,791 | $3,635 | $3,734 | $2,805 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 19,933 | 327 | 595 | 299 | 319 |
| TOTAL | $19,933 | $327 | $595 | $299 | $319 |
| Total Liabilities | $26,292 | $13,118 | $4,230 | $4,033 | $3,124 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 42,606 | 34,647 | 28,355 | 26,503 | 19,486 |
| Common Shares | 4 | 3 | 3 | 2 | 2 |
| Retained earnings | -196,131 | -181,310 | -163,704 | -153,869 | -146,607 |
| TOTAL | $-4,255 | $3,126 | $16,851 | $13,156 | $18,331 |
| Total Liabilities And Equity | $22,037 | $16,244 | $21,082 | $17,189 | $21,455 |